WST logo

WST
West Pharmaceutical Services, Inc.

852
Mkt Cap
$22.33B
Volume
267,545.00
52W High
$330.88
52W Low
$203.74
PE Ratio
42.26
WST Fundamentals
Price
$316.52
Prev Close
$316.13
Open
$312.61
50D MA
$275.95
Beta
0.69
Avg. Volume
967,554.87
EPS (Annual)
$6.79
P/B
7.50
Rev/Employee
$284,694.44
$19,537.58
Loading...
Loading...
News
all
press releases
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
News Placeholder
More News
News Placeholder
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
News Placeholder
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
News Placeholder
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
News Placeholder
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?
News Placeholder
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
News Placeholder
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
News Placeholder
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.
News Placeholder
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
News Placeholder
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available